Early QMSR Lessons, AI Oversight And RWE On Regulatory Agenda At AdvaMed’s MedTech Conference
The MedTech Conference, hosted by AdvaMed, will bring more than 4,000 industry leaders to Boston Oct. 18–21 to discuss major medtech trends including AI, real-world evidence, regulatory policy, quality systems and global market access.
Medtech Insight - October 14, 2026

UK Amoxicillin Prices Spike As Rivastigmine Continues To Climb
As steep price rises continue to be a fixture of the UK generics market – with multiple molecules in different presentations seeing their average prices doubling, trebling or even more than quadrupling in September – Generics Bulletin and WaveData look at the latest trends.
Generics Bulletin - October 14, 2026

EU Self-Care Industry Turns To Member States To Keep Topical Antimicrobials OTC
With the revised EU pharma directive making antimicrobials prescription-only by default, AESGP and national associations in France, Germany and Italy tell HBW Insight how they will push member states to keep topical products OTC.
HBW Insight - October 14, 2026

Biocon Claims Earliest Pertuzumab Launch Dates With Perjeta Settlement
Following a recent endorsement from the EMA, Biocon has moved to secure launch dates for its Pebrilzo biosimilar to Perjeta across the world, including a Q1 2027 launch in Europe. But with Organon already holding EU and US approvals for its own Henlius-partnered pertuzumab Poherdy, a showdown looms.
Generics Bulletin - October 14, 2026

Xbrane Edges Closer To Opdivo Biosimilar Finish Line With Completed Trial Recruitment
Xdivane, a nivolumab biosimilar co-developed by Xbrane and Intas, has reached a trial recruitment milestone, as approvals in the US and Europe are anticipated as soon as Opdivo exclusivity ends.
Generics Bulletin - October 14, 2026

How PAGB Won UK Exemption From EU-Wide OTC Antimicrobial Reverse Switch
HBW Insight speaks to PAGB CEO Michelle Riddalls about how she led a successful campaign to exempt the UK from the EU-wide OTC antimicrobial reverse switch, using data on the cost of extra GP appointments to win over government.
HBW Insight - October 14, 2026

‘AI-Native’ Notified Body Scarlet Bucks Sector Woes With $50m Funding
Scarlet specializes in certifying AI-enabled medical devices as well as paring assessors with AI agents for greater speed.
Medtech Insight - October 14, 2026

Beyond Harvesting: How Pfizer Is Using Mature Brands As A Test Bed For Innovation
Senior Pfizer executive outlines how the company is using its mature and established brands as a beachhead to test new business and technology models, unlocking value for that portfolio while generating lessons for the broader firm.
Scrip - October 14, 2026

Taming AAV Immunogenicity Is Gene Therapy’s Defining Challenge
AAV gene therapy has transformed outcomes for patients with rare diseases, but immune responses to the vector are limiting who can be treated, how safely, and for how long. Genethon’s Klaudia Kuranda explains how her organization is attacking the problem from several angles at once.
In Vivo - October 14, 2026

BioJapan: Japanese Ventures Expand Horizons In Radiopharma, Neuron-Targeted Delivery
BioJapan shines spotlight on domestic ventures including LinqMed and its pre-NDA radioisotope for malignant glioma and Jiksak's novel neuron-targeting drug delivery technology.
Scrip - October 14, 2026

Finance Watch: 2026 Biopharma IPO Total Doubles Last Year’s Number
Public Company Edition: TRexBio and Retension grossed $116.7m and $45m, respectively, in the third quarter’s first two initial public offerings, bringing the US IPO total to 24 so far in 2026 versus 12 for all of 2025. In other financings, Vaxcyte closed a $1.15bn follow-on offering.
Scrip - October 14, 2026

Counterfeit Fight: Industry Groups Push EU to Tighten Online Platform Liability Rules
Cosmetics Europe and eight other industry-related groups said online marketplaces, social media and live-streaming services should have to demonstrate that they are keeping counterfeit and unsafe products away from EU consumers, or lose their liability protection under the Digital Services Act.
HBW Insight - October 14, 2026